ClinicalTrials.gg
CompletedNCT03796182Updated Feb 5, 2020Results posted

Study of PF 04965842 Effect on MATE1/2K Activity in Healthy Participants

A Phase 1 interventional study of Metformin and PF-04965842 in Healthy, sponsored by Pfizer. Completed at 1 site in Belgium. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-02-05.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing abrocitinib in Dermatitis, Atopic — 5 open to participants now, 5 under way, 2 of them phase 3. abrocitinib · Dermatitis, Atopic.

Enrollment
19th of 20
12 · median 150
Started
2019
with 1 other
Phase 1
3 of 20
none open now
Registered
8th of 20
by date
Lead sponsor
15 of 20
Pfizer

Among the 20 studies testing abrocitinib in Dermatitis, Atopic, this one is the 19th largest by enrollment, is one of 2 that started in 2019, is one of 3 in phase 1, and was the 8th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

5 of the 20 studies testing abrocitinib in Dermatitis, Atopic are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About abrocitinib

abrocitinib: first FDA approval 2022 (CIBINQO), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing abrocitinib in Dermatitis, Atopic, or all of them as a file.
02

Study summary

This is a Phase 1, randomized, 2 way crossover, open label study of the effect of PF-04965842 on metformin (a probe for MATE1/2K activity) PK in healthy adult participants. The effect of PF-04965842 on N1-methylnicotinamide (NMN; an endogenous biomarker for MATE1/2K) PK and its correlation to the effect on metformin PK will also be assessed. Participants will be randomized to 1 of 2 treatment sequences as described below. A total of 12 healthy male and/or female participants will be enrolled in the study so that 6 participants will be enrolled in each treatment sequence. Each treatment sequence will consist of 2 periods.

Read the detailed description

This is a Phase 1, randomized, 2 way crossover, open label study of the effect of PF-04965842 on metformin (a probe for MATE1/2K activity) PK in healthy adult participants. The effect of PF-04965842 on N1-methylnicotinamide (NMN; an endogenous biomarker for MATE1/2K) PK and its correlation to the effect on metformin PK will also be assessed. Participants will be randomized to 1 of 2 treatment sequences as described below. A total of 12 healthy male and/or female participants will be enrolled in the study so that 6 participants will be enrolled in each treatment sequence. Each treatment sequence will consist of 2 periods. Participants who discontinue from the study may be replaced at the sponsor's discretion. The replacement participant will receive the same treatment sequence as the participant who discontinued.

Participants will be screened within 28 days of the first dose of investigational product. Participants will report to the clinical research unit (CRU) the day prior to Day 1 (ie Day -1) dosing in Period 1 for both treatment sequences. In both sequences, participants will remain in the CRU for a total of 8 days and 7 nights (including Period 1 and Period 2). There will be a minimum 4 day washout period between metformin dosing events. NMN and metformin PK will be assessed in plasma and urine over 24 and 48 hours, respectively.

03

Conditions studied

  • Healthy

Browse trials for

Keywords

  • Phase 1
  • Metformin
  • Atopic dermatitis
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants who are overtly healthy as determined by medical evaluation including a detailed medical history, complete physical examination, laboratory tests, and cardiovascular tests.
  • Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
  • Female participants who are of child bearing potential must not be intending to become pregnant, currently pregnant, or lactating.
  • (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lb).
  • Capable of giving signed .

Exclusion criteria

Exclusion Criteria:

  • Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease.
  • Any condition possibly affecting drug absorption (eg, gastrectomy).
  • History of (HIV), virus, or virus infection; positive testing for HIV, hepatitis B surface antigen (HepBsAg), hepatitis B core antibody (HepBcAb), or hepatitis C virus antibody (HCVAb).
  • Other acute or chronic medical or psychiatric condition including recent (within the past year).
  • Evidence or history of clinically significant dermatological condition (eg, atopic dermatitis or psoriasis) or visible rash present during physical examination.
  • Clinically relevant history of lactic acidosis.
  • Use of prescription or nonprescription drugs and dietary and herbal supplements within 7 days or 5 half lives (whichever is longer) prior to the first dose of product.
  • A positive urine drug test.
  • Selected laboratory abnormalities.
  • History of regular alcohol consumption exceeding 14 drinks/week for female participants or 21 drinks/week for male participants (1 drink = 5 ounces [150 mL] of wine or 12 ounces [360 mL] of beer or 1.5 ounces [45 mL] of hard liquor) within 6 months before screening.
  • Known relevant history of elevated liver function tests (LFTs).
  • History of tuberculosis (TB) (active or latent)
  • Any history of chronic infections, any history of recurrent infections, any history of latent infections, or any acute infection within 2 weeks of baseline.
  • History of disseminated herpes zoster, or disseminated herpes simplex, or recurrent localized dermatomal herpes zoster.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Sequence 1

    Patients in sequence 1 will received treatment A (metformin) in Period 1 then complete at least 4 days of washout and continue to period 2 where treatment B (PF-04965842 + metformin) will be administered.

    Drug: Metformin · Drug: PF-04965842

  • Experimental
    Sequence 2

    Patients in Sequence 2 will start treatment B (PF-04965842 + metformin) then go through a washout period of at least 4 days and continue to Period 2 where treatment A (metformin) will be administered.

    Drug: Metformin · Drug: PF-04965842

Interventions

  • Commercially available metformin (GLUCOPHAGE®) as 500 mg tablets.

    Also known as: Glucophage

  • PF 04965842 100 mg tablets

06

What researchers measure

Primary outcomes

  1. Renal Clearance (CLr) of Metformin

    CLr was calculated as cumulative amount of drug recovered unchanged in urine during the dosing interval (Ae) divided by area under the plasma concentration time-curve from time zero to end of dosing interval (AUCtau).

    Time frame: For both Period 1 and Period 2 at intervals of 0-12, 12-24, 24-36, and 36-48 hours post metformin dose

Secondary outcomes

  1. Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of Metformin

    AUCinf is a measure of the serum concentration of the drug over time. It was used to characterize drug absorption.

    Time frame: Pre-dose and at 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-dose of metformin on Day 1 for both Period 1 and Period 2

  2. Maximum Plasma Concentration (Cmax) of Metformin

    Cmax is maximum observed plasma concentration.

    Time frame: Pre-dose and at 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-dose of metformin on Day 1 for both Period 1 and Period 2

  3. Time for Cmax (Tmax) of Metformin

    Tmax of metformin administrated with or without PF-04965842.

    Time frame: Pre-dose and at 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-dose of metformin on Day 1 for both Period 1 and Period 2

  4. Area Under the Plasma Concentration Time Profile From Time 0 to the Time of Last Quantifiable Concentration (AUClast) of Metformin

    AUClast of metformin administrated with or without PF-04965842.

    Time frame: Pre-dose and at 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-dose of metformin on Day 1 for both Period 1 and Period 2

  5. Apparent Clearance (CL/F) of Metformin

    CL/F is a quantitative measure of the rate at which drug was removed from the blood.

    Time frame: Pre-dose and at 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-dose of metformin on Day 1 for both Period 1 and Period 2

  6. Apparent Volume of Distribution (Vz/F) of Metformin

    Vz/F is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.

    Time frame: Pre-dose and at 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-dose of metformin on Day 1 for both Period 1 and Period 2

  7. Terminal Half-life (t1/2) of Metformin

    t1/2 is the time measured for the plasma concentration to decrease by one half.

    Time frame: Pre-dose and at 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-dose of metformin on Day 1 for both Period 1 and Period 2

  8. Cumulative Amount of Drug Recovered Unchanged in Urine From 0 to 48 Hours (Ae) of Metformin

    Ae is the cumulative amount of drug recovered unchanged in urine during the dosing interval. Cumulative amount was calculated as sum of urine drug concentration in sample volume for each collection interval. Sample volume = (urine weight in gram \[g\]/1.020), where 1.020 g/mL is the approximate specific gravity of urine.

    Time frame: For both Period 1 and Period 2 at intervals of 0-12, 12-24, 24-36, and 36-48 hours post metformin dose

  9. Percent of Dose Recovered Unchanged in Urine From 0 to 24 Hours (Ae%) of Metformin

    Ae% is percent of dose recovered unchanged in urine from 0 to 24 hours post-dose of metformin.

    Time frame: For both Period 1 and Period 2 at intervals of 0-12 and 12-24 hours post metformin dose

  10. Number of Participants With Laboratory Abnormalities

    Laboratory parameters included: hematology (hemoglobin, hematocrit, erythrocytes, ery. mean corpuscular volume, ery. mean corpuscular hemoglobin, ery. mean corpuscular HGB concentration, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils, monocytes, activated partial thromboplastin time, prothrombin time, prothrombin intl. normalized ratio, large unstained cells/leukocytes and large unstained cells), clinical chemistry (bilirubin, direct bilirubin, indirect bilirubin, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, protein, albumin, blood urea nitrogen, urea, creatinine, urate, sodium, potassium, chloride, calcium, bicarbonate, urobilinogen and glucose -FASTING), urinalysis (specific gravity, pH, urine glucose, ketones, urine protein, urine hemoglobin, urine bilirubin, nitrite and leukocytes). Clinical significance of laboratory parameters is determined at the investigator's discretion.

    Time frame: Screening (within 28 days prior to Day 1) to Day 7

  11. Number of Participants With Categorical Vital Signs Meeting Pre-defined Criteria

    Criteria for change in vital signs: pulse rate value less than (\<) 40 beats per minute (bpm) or value over than (\>) 120 bpm, systolic blood pressure (SBP) value \< 90 millimeter of mercury (mmHg) or change from baseline (Chg) equal to or over than (≥) 30 mmHg increase or ≥ Chg 30 mmHg decrease, diastolic blood pressure (DBP) value \< 50 mmHg or Chg ≥ 20 mmHg increase or Chg ≥ 20 mmHg decrease.

    Time frame: Screening (within 28 days prior to Day 1) to Day 7

  12. Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) (All Causalities and Treatment-related)

    AEs with all causalities were any untoward medical occurrences in a study subject administered a product or medical device which did not necessarily had causal relationship with the treatment or usage. An SAE was an AE resulting in any of the following endpoints or deemed significant for any other reason: death; life threatening (immediate risk of death); inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; or considered to be an important medical event. Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment-emergent are events between first dose of study drug and up to 35 days after last dose that were absent before treatment or that worsened relative to pretreatment state.

    Time frame: Day 1 up to Day 40 (35 days after the last dose of metformin)

  13. Percentage of Participants With Treatment-Emergent AEs and SAEs (All Causalities and Treatment-related)

    AEs with all causalities were any untoward medical occurrences in a study subject administered a product or medical device which did not necessarily had causal relationship with the treatment or usage. An SAE was an AE resulting in any of the following endpoints or deemed significant for any other reason: death; life threatening (immediate risk of death); inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; or considered to be an important medical event. Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment-emergent are events between first dose of study drug and up to 35 days after last dose that were absent before treatment or that worsened relative to pretreatment state.

    Time frame: Day 1 up to Day 40 (35 days after the last dose of metformin)

07

Results

Posted Feb 5, 2020

Participant flow

Period 1
Participant flow — Period 1
MilestoneMetformin Then Metformin + PF-04965842Metformin + PF-04965842 Then Metformin
Started66
Completed66
Not completed00
Washout Period
Participant flow — Washout Period
MilestoneMetformin Then Metformin + PF-04965842Metformin + PF-04965842 Then Metformin
Started66
Completed66
Not completed00
Period 2
Participant flow — Period 2
MilestoneMetformin Then Metformin + PF-04965842Metformin + PF-04965842 Then Metformin
Started66
Completed66
Not completed00

Outcome measures

PrimaryRenal Clearance (CLr) of Metformin

CLr was calculated as cumulative amount of drug recovered unchanged in urine during the dosing interval (Ae) divided by area under the plasma concentration time-curve from time zero to end of dosing interval (AUCtau).

Time frame:
For both Period 1 and Period 2 at intervals of 0-12, 12-24, 24-36, and 36-48 hours post metformin dose
Reported as:
Geometric mean · litre per hour (L/hr)
Renal Clearance (CLr) of Metformin
litre per hour (L/hr)Metformin + PF-04965842Metformin
Renal Clearance (CLr) of Metformin32.18 ± 3933.33 ± 28
Statistical analysis
  • Metformin + PF-04965842 vs Metformin · Ratio: 98.50 · 90% CI 82.09 to 118.20
SecondaryArea Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of Metformin

AUCinf is a measure of the serum concentration of the drug over time. It was used to characterize drug absorption.

Time frame:
Pre-dose and at 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-dose of metformin on Day 1 for both Period 1 and Period 2
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*hr/mL)
Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of Metformin
nanogram*hour per milliliter (ng*hr/mL)Metformin + PF-04965842Metformin
Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of Metformin5050 ± 165202 ± 19
Statistical analysis
  • Metformin + PF-04965842 vs Metformin · Ratio: 93.49 · 90% CI 85.15 to 102.65
SecondaryMaximum Plasma Concentration (Cmax) of Metformin

Cmax is maximum observed plasma concentration.

Time frame:
Pre-dose and at 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-dose of metformin on Day 1 for both Period 1 and Period 2
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Maximum Plasma Concentration (Cmax) of Metformin
nanogram per milliliter (ng/mL)Metformin + PF-04965842Metformin
Maximum Plasma Concentration (Cmax) of Metformin634.7 ± 14720.7 ± 20
Statistical analysis
  • Metformin + PF-04965842 vs Metformin · Ratio: 88.07 · 90% CI 80.99 to 95.76
SecondaryTime for Cmax (Tmax) of Metformin

Tmax of metformin administrated with or without PF-04965842.

Time frame:
Pre-dose and at 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-dose of metformin on Day 1 for both Period 1 and Period 2
Reported as:
Median · Hours (hrs)
Time for Cmax (Tmax) of Metformin
Hours (hrs)Metformin + PF-04965842Metformin
Time for Cmax (Tmax) of Metformin4.00 (2.00 to 4.00)4.00 (1.00 to 4.00)
SecondaryArea Under the Plasma Concentration Time Profile From Time 0 to the Time of Last Quantifiable Concentration (AUClast) of Metformin

AUClast of metformin administrated with or without PF-04965842.

Time frame:
Pre-dose and at 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-dose of metformin on Day 1 for both Period 1 and Period 2
Reported as:
Geometric mean · ng*h/mL
Area Under the Plasma Concentration Time Profile From Time 0 to the Time of Last Quantifiable Concentration (AUClast) of Metformin
ng*h/mLMetformin + PF-04965842Metformin
Area Under the Plasma Concentration Time Profile From Time 0 to the Time of Last Quantifiable Concentration (AUClast) of Metformin4849 ± 185145 ± 18
Statistical analysis
  • Metformin + PF-04965842 vs Metformin · Ratio: 94.25 · 90% CI 88.19 to 100.73
SecondaryApparent Clearance (CL/F) of Metformin

CL/F is a quantitative measure of the rate at which drug was removed from the blood.

Time frame:
Pre-dose and at 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-dose of metformin on Day 1 for both Period 1 and Period 2
Reported as:
Geometric mean · L/hr
Apparent Clearance (CL/F) of Metformin
L/hrMetformin + PF-04965842Metformin
Apparent Clearance (CL/F) of Metformin98.97 ± 1696.13 ± 19
SecondaryApparent Volume of Distribution (Vz/F) of Metformin

Vz/F is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.

Time frame:
Pre-dose and at 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-dose of metformin on Day 1 for both Period 1 and Period 2
Reported as:
Geometric mean · liter (L)
Apparent Volume of Distribution (Vz/F) of Metformin
liter (L)Metformin + PF-04965842Metformin
Apparent Volume of Distribution (Vz/F) of Metformin1087 ± 421211 ± 37
SecondaryTerminal Half-life (t1/2) of Metformin

t1/2 is the time measured for the plasma concentration to decrease by one half.

Time frame:
Pre-dose and at 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-dose of metformin on Day 1 for both Period 1 and Period 2
Reported as:
Mean · hrs
Terminal Half-life (t1/2) of Metformin
hrsMetformin + PF-04965842Metformin
Terminal Half-life (t1/2) of Metformin8.318 ± 4.25089.261 ± 3.5165
SecondaryCumulative Amount of Drug Recovered Unchanged in Urine From 0 to 48 Hours (Ae) of Metformin

Ae is the cumulative amount of drug recovered unchanged in urine during the dosing interval. Cumulative amount was calculated as sum of urine drug concentration in sample volume for each collection interval. Sample volume = (urine weight in gram \[g\]/1.020), where 1.020 g/mL is the approximate specific gravity of urine.

Time frame:
For both Period 1 and Period 2 at intervals of 0-12, 12-24, 24-36, and 36-48 hours post metformin dose
Reported as:
Median · milligram (mg)
Cumulative Amount of Drug Recovered Unchanged in Urine From 0 to 48 Hours (Ae) of Metformin
milligram (mg)Metformin + PF-04965842Metformin
Cumulative Amount of Drug Recovered Unchanged in Urine From 0 to 48 Hours (Ae) of Metformin168.0 (70.7 to 210)170.5 (114 to 248)
SecondaryPercent of Dose Recovered Unchanged in Urine From 0 to 24 Hours (Ae%) of Metformin

Ae% is percent of dose recovered unchanged in urine from 0 to 24 hours post-dose of metformin.

Time frame:
For both Period 1 and Period 2 at intervals of 0-12 and 12-24 hours post metformin dose
Reported as:
Median · percentage of dose
Percent of Dose Recovered Unchanged in Urine From 0 to 24 Hours (Ae%) of Metformin
percentage of doseMetformin + PF-04965842Metformin
Percent of Dose Recovered Unchanged in Urine From 0 to 24 Hours (Ae%) of Metformin33.60 (14.1 to 42.0)34.05 (22.7 to 49.7)
SecondaryNumber of Participants With Laboratory Abnormalities

Laboratory parameters included: hematology (hemoglobin, hematocrit, erythrocytes, ery. mean corpuscular volume, ery. mean corpuscular hemoglobin, ery. mean corpuscular HGB concentration, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils, monocytes, activated partial thromboplastin time, prothrombin time, prothrombin intl. normalized ratio, large unstained cells/leukocytes and large unstained cells), clinical chemistry (bilirubin, direct bilirubin, indirect bilirubin, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, protein, albumin, blood urea nitrogen, urea, creatinine, urate, sodium, potassium, chloride, calcium, bicarbonate, urobilinogen and glucose -FASTING), urinalysis (specific gravity, pH, urine glucose, ketones, urine protein, urine hemoglobin, urine bilirubin, nitrite and leukocytes). Clinical significance of laboratory parameters is determined at the investigator's discretion.

Time frame:
Screening (within 28 days prior to Day 1) to Day 7
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities
ParticipantsMetformin + PF-04965842Metformin
Number of Participants With Laboratory Abnormalities00
SecondaryNumber of Participants With Categorical Vital Signs Meeting Pre-defined Criteria

Criteria for change in vital signs: pulse rate value less than (\<) 40 beats per minute (bpm) or value over than (\>) 120 bpm, systolic blood pressure (SBP) value \< 90 millimeter of mercury (mmHg) or change from baseline (Chg) equal to or over than (≥) 30 mmHg increase or ≥ Chg 30 mmHg decrease, diastolic blood pressure (DBP) value \< 50 mmHg or Chg ≥ 20 mmHg increase or Chg ≥ 20 mmHg decrease.

Time frame:
Screening (within 28 days prior to Day 1) to Day 7
Reported as:
Count of participants · Participants
Number of Participants With Categorical Vital Signs Meeting Pre-defined Criteria
ParticipantsMetformin + PF-04965842Metformin
Supine DBP Value < 50 mmHg00
Supine DBP Chg ≥ 20 mmHg increase00
Supine DBP Chg ≥ 20 mmHg decrease00
Supine pulse rate Value < 40 bpm00
Supine pulse rate Value > 120 bpm00
Supine SBP Value < 90 mmHg00
Supine SBP Chg ≥ 30 mmHg increase00
Supine SBP Chg ≥ 30 mmHg decrease00
SecondaryNumber of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) (All Causalities and Treatment-related)

AEs with all causalities were any untoward medical occurrences in a study subject administered a product or medical device which did not necessarily had causal relationship with the treatment or usage. An SAE was an AE resulting in any of the following endpoints or deemed significant for any other reason: death; life threatening (immediate risk of death); inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; or considered to be an important medical event. Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment-emergent are events between first dose of study drug and up to 35 days after last dose that were absent before treatment or that worsened relative to pretreatment state.

Time frame:
Day 1 up to Day 40 (35 days after the last dose of metformin)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) (All Causalities and Treatment-related)
ParticipantsMetformin + PF-04965842Metformin
AEs (all causalities)64
AEs (treatment-related)54
SAEs (all causalities)00
SAEs (treatment-related)00
SecondaryPercentage of Participants With Treatment-Emergent AEs and SAEs (All Causalities and Treatment-related)

AEs with all causalities were any untoward medical occurrences in a study subject administered a product or medical device which did not necessarily had causal relationship with the treatment or usage. An SAE was an AE resulting in any of the following endpoints or deemed significant for any other reason: death; life threatening (immediate risk of death); inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; or considered to be an important medical event. Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment-emergent are events between first dose of study drug and up to 35 days after last dose that were absent before treatment or that worsened relative to pretreatment state.

Time frame:
Day 1 up to Day 40 (35 days after the last dose of metformin)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-Emergent AEs and SAEs (All Causalities and Treatment-related)
percentage of participantsMetformin + PF-04965842Metformin
AEs (all causalities)50.033.3
AEs (treatment-related)41.733.3
SAEs (all causalities)0.00.0
SAEs (treatment-related)0.00.0

Adverse events

Collected over Day 1 up to Day 40 (35 days after the last dose of metformin). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Metformin + PF-049658420/12 (0%)0/12 (0%)6/12 (50%)
Metformin0/12 (0%)0/12 (0%)4/12 (33.3%)
Most frequent other events
Most frequent other events
EventMetformin + PF-04965842Metformin
DiarrhoeaGastrointestinal disorders4/123/12
Abdominal discomfortGastrointestinal disorders1/120/12
Anorectal discomfortGastrointestinal disorders1/120/12
NauseaGastrointestinal disorders1/120/12
FatigueGeneral disorders0/121/12
NasopharyngitisInfections and infestations0/121/12
Muscle spasmsMusculoskeletal and connective tissue disorders0/121/12
Neck painMusculoskeletal and connective tissue disorders1/120/12

Baseline characteristics

All 12 participants who were randomized to study treatment.

Age, Continuous
Age, Continuous(Years)All Participants
Mean39.0 ± 8.42
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female0
Male12
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)All Participants
Hispanic or Latino1
Not Hispanic or Latino11
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Participants
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander1
Black or African American1
White10
More than one race0
Unknown or Not Reported0
08

Study locations

1 site
  • Pfizer Clinical Research Unit
    Brussels, B-1070, Belgium
09

References and documents

Publications

  • Vourvahis M, Byon W, Chang C, Le V, Diehl A, Graham D, Tripathy S, Raha N, Luo L, Mathialagan S, Dowty M, Rodrigues AD, Malhotra B. Evaluation of the Effect of Abrocitinib on Drug Transporters by Integrated Use of Probe Drugs and Endogenous Biomarkers. Clin Pharmacol Ther. 2022 Sep;112(3):665-675. doi: 10.1002/cpt.2594. Epub 2022 May 9. PubMed 35344588 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2019 to primary completion in Feb 2019, 1 month.

Results were first posted in Feb 2020, 11 months after primary completion.

Of 114 industry-sponsored phase 1 interventional studies under Dermatitis, Atopic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 1 month is below that.

Counting every sponsor, half of 131 studies reached it within 13 months; a quarter within 5 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2019
First posted
Jan 8, 2019
StartActual
Jan 10, 2019
Primary completionActual
Feb 13, 2019
CompletionActual
Mar 12, 2019
Results first posted
Feb 5, 2020
Last update
Feb 5, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03796182
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jan 8, 2019
Start date
Jan 10, 2019
Primary completion
Feb 13, 2019
Completion
Mar 12, 2019
Results posted
Feb 5, 2020
Last update
Feb 5, 2020

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abrocitinib

Start the discussion